Table 2.
Clinical, laboratory findings, and radiological manifestations in the two groups on admission.
| All (n = 152) | ACEI/ARB group (n = 38) | Control group (n = 114) | P | |
|---|---|---|---|---|
| Initial symptoms, number (%) | ||||
| Fever (≥37.3°C) | 140 (92%) | 35 (92%) | 105 (92%) | 0.981 |
| Cough | 109 (72%) | 27 (70%) | 82 (72%) | 0.866 |
| Productive cough | 60 (39%) | 16 (42%) | 44 (39%) | 0.605 |
| Hemoptysis | 3 (2%) | 1 (3%) | 2 (2%) | 0.263 |
| Dyspnea | 78 (51%) | 20 (53%) | 58 (51%) | 0.432 |
| Fatigue or myalgia | 67 (44%) | 16 (43%) | 51 (45%) | 0.619 |
| Diarrhea | 46 (30%) | 12 (31%) | 34 (30%) | 0.764 |
| Initial signs, mean ± SD | ||||
| Highest temperature, °C | 38.4 ± 0.7 | 38.5 ± 1.1 | 38.3 ± 0.4 | 0.461 |
| Respiratory rate, breaths/min | 23 ± 3 | 22 ± 3 | 23 ± 3 | 0.709 |
| Heart rate, beats/min | 96 ± 11 | 97 ± 8 | 96 ± 14 | 0.338 |
| Systolic blood pressure, mmHg | 123 ± 10 | 116 ± 14 | 124 ± 13 | 0.031a |
| SpO2, % | 94 ± 4 | 93 ± 3 | 94 ± 4 | 0.741 |
| FiO2, % | 40 ± 18 | 42 ± 15 | 40 ± 17 | 0.302 |
| Laboratory examination, mean ± SD | ||||
| Blood routine | ||||
| WBC, *109/L | 5.94 ± 3.00 | 6.27 ± 3.21 | 5.80 ± 2.97 | 0.085 |
| Neutrophil count, *109/L | 4.40 ± 2.99 | 5.21 ± 3.29 | 4.39 ± 3.01 | 0.097 |
| Lymphocytes, *109/L | 0.89 ± 0.40 | 0.76 ± 0.31 | 1.01 ± 0.45 | 0.027a |
| Biochemical examination | ||||
| ALT, U/L | 43 ± 4 | 42 ± 4 | 43 ± 4 | 0.747 |
| AST, U/L | 40 ± 5 | 44 ± 4 | 40 ± 5 | 0.841 |
| TBIL, mmol/L | 11.3 ± 5.2 | 11.0 ± 5.9 | 11.4 ± 5.0 | 0.660 |
| Scr, μmol/L | 79.2 ± 2.7 | 77.5 ± 2.2 | 80.1 ± 3.6 | 0.915 |
| LDH, U/L | 295 ± 89 | 301 ± 77 | 294 ± 91 | 0.617 |
| TnT, pg/ml | 11 ± 1 | 12 ± 1 | 11 ± 1 | 0.770 |
| NT-proBNP, pg/ml | 401 ± 55 | 411 ± 55 | 397 ± 51 | 0.528 |
| Inflammatory factors | ||||
| IL-1β, pg/ml | 8.02 ± 0.33 | 6.20 ± 0.38 | 9.30 ± 0.31 | 0.020a |
| IL-2R, U/ml | 796.02 ± 27.40 | 724.25 ± 52.30 | 807.23 ± 26.21 | 0.246 |
| IL-6, pg/ml | 47.11 ± 3.26 | 31.86 ± 4.07 | 48.47 ± 3.11 | 0.041a |
| IL-8, pg/ml | 46.03 ± 1.85 | 34.66 ± 1.90 | 47.93 ± 1.21 | 0.027a |
| IL-10, pg/ml | 6.37 ± 0.37 | 9.91 ± 0.42 | 5.26 ± 0.21 | 0.012b |
| TNF-α, pg/ml | 11.21 ± 0.44 | 6.11 ± 0.88 | 12.73 ± 0.26 | <0.001b |
| PCT, ng/ml | 0.27 ± 0.07 | 0.26 ± 0.03 | 0.29 ± 0.08 | 0.619 |
| Coagulation function | ||||
| PT, s | 14 ± 3 | 14 ± 1 | 14 ± 1 | 0.995 |
| APTT, s | 42 ± 5 | 44 ± 3 | 42 ± 5 | 0.881 |
| D-Dimer, μg/ml | 2.19 ± 0.44 | 2.33 ± 0.47 | 2.12 ± 0.46 | 0.448 |
| Chest CT manifestations, number (%) | ||||
| Bilateral lesion | 82 (54%) | 19 (49%) | 63 (55%) | 0.374 |
| GGO | 89 (59%) | 19 (49%) | 70 (61%) | 0.310 |
| Consolidation | 36 (24%) | 11 (29%) | 25 (22%) | 0.229 |
a
P < 0.05;
b
P < 0.01; SpO2, saturation of peripheral oxygen; FiO2, fraction of inspiration; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL, total bilirubin; Scr, creatinine; LDH; lactate dehydrogenase; TnT, troponin T; NT-proBNP, N-terminal pro-brain natriuretic peptide; IL-1β, interleukin-1β; IL-2R, interleukin-2R; IL-6, interleukin-6; IL-8, interleukin-8; IL-10, interleukin-10; TNF-α, tumor necrosis factor-α; PCT, procalcitonin; PT, prothrombin time; APTT, activated partial thromboplastin time; GGO, ground-glass opacity.